Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes

European Journal of Clinical Pharmacology

Volumn 60, Issue 9, 2004, Pages 623-628

  Miura, M ^a   Tada, H ^a   Yasui Furukori, N ^b   Uno, T ^c   Sugawara, K ^c   Tateishi, T ^b   Suzuki, T ^a  

^a AKITA UNIVERSITY HOSPITAL   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c HIROSAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

5 Hydroxylansoprazole; Enantiomer; Lansoprazole

Indexed keywords

5 HYDROXYLANSOPRAZOLE; CYTOCHROME P450 2C19; DRUG METABOLITE; LANSOPRAZOLE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENANTIOMER; ENZYME POLYMORPHISM; FEMALE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; MALE; NORMAL HUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; STEREOCHEMISTRY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; ANTI-ULCER AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENOTYPE; H(+)-K(+)-EXCHANGING ATPASE; HALF-LIFE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; STEREOISOMERISM; TIME FACTORS;

EID: 11244249549     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0809-1     Document Type: Article

References (15)

1. Nagaya H, Satoh H, Maki Y (1990) Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther 252:1289-1295
2. +)-ATPase activity in canine gastric microsomes and acid formation in isolated canine parietal cells. Biochem Pharmacol 42:1875-1878
3. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A (1996) Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 277:805-816
4. Katsuki H, Nakamura C, Arimori K, Fujiyama S, Nakano M (1997) Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. Eur J Clin Pharmacol 52:391-396
5. Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domerque J, Joyeux H, Cosme J, Guengerich FP (1995) Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 47:410-418
6. Sohn DR, Kwon JT, Kim HK, Ishizaki T (1997) Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status. Clin Pharmacol Ther 61:574-582
7. Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, Hohda T, Sirasaka D, Tamura T, Tanigawara Y, Kasuga M, Okumura K (2001) CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 18:721-727
8. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T (2001) Effect of high-dose lansoprazole on intragastic pH in subjects who are homozyaous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 70:484-492
9. Kim K, Shon J, Park J, Yoon Y, Kim M, Yun D, Kim M, Cha I, Hyun M, Shin J (2002) Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19. Clin Pharmacol Ther 72:90-99
10. Katsuki H, Hamada A, Nakamura C, Arimori K, Nakano M (2001) Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes. Eur J Clin Pharmacol 57:709-715
11. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598
12. Miura M, Tada H, Suzuki T (2004) Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction. J Chromatogr B 804:389-395
13. Ieiri I, Kishimoto Y, Okochi H, Momiyama K, Morita T, Kitano M, Morisawa T, Fukushima Y, Nakagawa K, Hasegawa J, Otsubo K, Ishizaki T (2001) Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. Eur J Clin Pharmacol 57:485-492
14. Kim KA, Kim MJ, Park JY, Shon JH, Yoon YR, Lee SS, Liu KH, Chun JH, Hyun MH, Shin JG (2003) Stereoselective metabolism of lansoprazole by human liver cytochrome p450 enzymes. Drug Metab Dispos 31:1227-1234
15. Inatomi N, Nagaya H, Ishisaka Y, Satoh H (1991) Effects of AG-1749 (Lansoprazole) and its metabolites on acid secretion and experimental ulcers. Jpn Pharmacol Ther 19:477-486 (in Japanese)